BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 36249685)

  • 1. Tumor-Infiltrating T Cells Can Be Expanded Successfully from Primary Uveal Melanoma after Separation from Their Tumor Environment.
    Gezgin G; Visser M; Ruano D; Santegoets SJ; de Miranda NFCC; van der Velden PA; Luyten GPM; van der Burg SH; Verdegaal EM; Jager MJ
    Ophthalmol Sci; 2022 Jun; 2(2):100132. PubMed ID: 36249685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of PD-1/PD-L1 expression in uveal melanoma: correlation with tumor-infiltrating lymphocytes and clinicopathological parameters.
    Singh L; Singh MK; Kenney MC; Jager MJ; Rizvi MA; Meel R; Lomi N; Bakhshi S; Sen S; Kashyap S
    Cancer Immunol Immunother; 2021 May; 70(5):1291-1303. PubMed ID: 33136179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adherent cell depletion promotes the expansion of renal cell carcinoma infiltrating T cells with optimal characteristics for adoptive transfer.
    Braun MW; Abdelhakim H; Li M; Hyter S; Pessetto Z; Koestler DC; Pathak HB; Dunavin N; Godwin AK
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33037114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunologic Characterization and T cell Receptor Repertoires of Expanded Tumor-infiltrating Lymphocytes in Patients with Renal Cell Carcinoma.
    Lee MH; Theodoropoulos J; Huuhtanen J; Bhattacharya D; Järvinen P; Tornberg S; Nísen H; Mirtti T; Uski I; Kumari A; Peltonen K; Draghi A; Donia M; Kreutzman A; Mustjoki S
    Cancer Res Commun; 2023 Jul; 3(7):1260-1276. PubMed ID: 37484198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expansion of tumor-infiltrating lymphocytes from head and neck squamous cell carcinoma to assess the potential of adoptive cell therapy.
    Choi S; Hossain M; Lee H; Baek J; Park HS; Lim CL; Han D; Park T; Kim JH; Gong G; Kweon MN; Lee HJ
    Cancer Immunol Immunother; 2024 Apr; 73(6):101. PubMed ID: 38630265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expansion and characterization of human melanoma tumor-infiltrating lymphocytes (TILs).
    Nguyen LT; Yen PH; Nie J; Liadis N; Ghazarian D; Al-Habeeb A; Easson A; Leong W; Lipa J; McCready D; Reedijk M; Hogg D; Joshua AM; Quirt I; Messner H; Shaw P; Crump M; Sharon E; Ohashi PS
    PLoS One; 2010 Nov; 5(11):e13940. PubMed ID: 21085676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook.
    Wu R; Forget MA; Chacon J; Bernatchez C; Haymaker C; Chen JQ; Hwu P; Radvanyi LG
    Cancer J; 2012; 18(2):160-75. PubMed ID: 22453018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T-cell Responses in the Microenvironment of Primary Renal Cell Carcinoma-Implications for Adoptive Cell Therapy.
    Andersen R; Westergaard MCW; Kjeldsen JW; Müller A; Pedersen NW; Hadrup SR; Met Ö; Seliger B; Kromann-Andersen B; Hasselager T; Donia M; Svane IM
    Cancer Immunol Res; 2018 Feb; 6(2):222-235. PubMed ID: 29301752
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinicopathological factors associated with tumor-infiltrating lymphocyte reactivity in breast cancer.
    Lee H; Kim YA; Kim Y; Park HS; Seo JH; Lee H; Gong G; Lee HJ
    Cancer Immunol Immunother; 2020 Nov; 69(11):2381-2391. PubMed ID: 32529292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors.
    Gros A; Robbins PF; Yao X; Li YF; Turcotte S; Tran E; Wunderlich JR; Mixon A; Farid S; Dudley ME; Hanada K; Almeida JR; Darko S; Douek DC; Yang JC; Rosenberg SA
    J Clin Invest; 2014 May; 124(5):2246-59. PubMed ID: 24667641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phenotype and function of T cells infiltrating visceral metastases from gastrointestinal cancers and melanoma: implications for adoptive cell transfer therapy.
    Turcotte S; Gros A; Hogan K; Tran E; Hinrichs CS; Wunderlich JR; Dudley ME; Rosenberg SA
    J Immunol; 2013 Sep; 191(5):2217-25. PubMed ID: 23904171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of BAP1 expression is associated with an immunosuppressive microenvironment in uveal melanoma, with implications for immunotherapy development.
    Figueiredo CR; Kalirai H; Sacco JJ; Azevedo RA; Duckworth A; Slupsky JR; Coulson JM; Coupland SE
    J Pathol; 2020 Apr; 250(4):420-439. PubMed ID: 31960425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expansion of tumor-infiltrating lymphocytes and their potential for application as adoptive cell transfer therapy in human breast cancer.
    Lee HJ; Kim YA; Sim CK; Heo SH; Song IH; Park HS; Park SY; Bang WS; Park IA; Lee M; Lee JH; Cho YS; Chang S; Jung J; Kim J; Lee SB; Kim SY; Lee MS; Gong G
    Oncotarget; 2017 Dec; 8(69):113345-113359. PubMed ID: 29371915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterisation of the protein expression of the emerging immunotherapy targets VISTA, LAG-3 and PRAME in primary uveal melanoma: insights from a southern French patient cohort.
    Lamas NJ; Lassalle S; Martel A; Nahon-Estève S; Macocco A; Zahaf K; Lalvee S; Fayada J; Lespinet-Fabre V; Bordone O; Pedeutour F; Baillif S; Hofman P
    Pathology; 2023 Dec; 55(7):929-944. PubMed ID: 37863710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adenovirus-mediated interleukin-2 production by tumors induces growth of cytotoxic tumor-infiltrating lymphocytes against human renal cell carcinoma.
    Mulders P; Tso CL; Pang S; Kaboo R; McBride WH; Hinkel A; Gitlitz B; Dannull J; Figlin R; Belldegrun A
    J Immunother; 1998 May; 21(3):170-80. PubMed ID: 9610908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer.
    Baxevanis CN; Dedoussis GV; Papadopoulos NG; Missitzis I; Stathopoulos GP; Papamichail M
    Cancer; 1994 Aug; 74(4):1275-82. PubMed ID: 7914469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multispectral imaging of formalin-fixed tissue predicts ability to generate tumor-infiltrating lymphocytes from melanoma.
    Feng Z; Puri S; Moudgil T; Wood W; Hoyt CC; Wang C; Urba WJ; Curti BD; Bifulco CB; Fox BA
    J Immunother Cancer; 2015; 3():47. PubMed ID: 26500776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T cells isolated from patients with checkpoint inhibitor-resistant melanoma are functional and can mediate tumor regression.
    Andersen R; Borch TH; Draghi A; Gokuldass A; Rana MAH; Pedersen M; Nielsen M; Kongsted P; Kjeldsen JW; Westergaard MCW; Radic HD; Chamberlain CA; Hölmich LR; Hendel HW; Larsen MS; Met Ö; Svane IM; Donia M
    Ann Oncol; 2018 Jul; 29(7):1575-1581. PubMed ID: 29688262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expansion of Tumor-reactive T Cells From Patients With Pancreatic Cancer.
    Meng Q; Liu Z; Rangelova E; Poiret T; Ambati A; Rane L; Xie S; Verbeke C; Dodoo E; Del Chiaro M; Löhr M; Segersvärd R; Maeurer MJ
    J Immunother; 2016; 39(2):81-9. PubMed ID: 26849077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parallel profiling of immune infiltrate subsets in uveal melanoma versus cutaneous melanoma unveils similarities and differences: A pilot study.
    Qin Y; Petaccia de Macedo M; Reuben A; Forget MA; Haymaker C; Bernatchez C; Spencer CN; Gopalakrishnan V; Reddy S; Cooper ZA; Fulbright OJ; Ramachandran R; Wahl A; Flores E; Thorsen ST; Tavera RJ; Conrad C; Williams MD; Tetzlaff MT; Wang WL; Gombos DS; Esmaeli B; Amaria RN; Hwu P; Wargo JA; Lazar AJ; Patel SP
    Oncoimmunology; 2017; 6(6):e1321187. PubMed ID: 28680759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.